Strategic Growth Citius is a late-stage biopharma focusing on first-in-class critical care products with anti-infectives and adjunct cancer care. Potential sales opportunity lies in accelerating commercialization of LYMPHIR and expanding into adjacent oncology supportive care indications and hospital-based infusion centers.

Recent Launch Momentum LYMPHIR launched in 2025 with a commercial push anticipated in Q2 2025 and reported LYMPHIR revenue in Q1 2026. Target hospitals, cancer centers, and specialty pharmacies should be prioritized for reimbursement discussions and payer negotiations to sustain revenue growth.

Strategic Partnerships Historical licensing and collaborations, including licensing Lymphir from Dr. Reddy’s and prior academic partnerships, suggest a receptiveness to co-development or distribution collaborations and regional licensing deals, presenting BD opportunities with regional distributors and academic networks.

Funding & Scale Funding activity includes a $15M financing and ongoing revenue streams in the $10M-$25M range with a $6M funding backdrop. Leverage this to approach strategic investors, joint ventures, or co-promotion agreements to accelerate market adoption and scale commercial operations.

Operational Focus Small company size (11-50 employees) implies nimbleness but resource constraints. Sales efforts should emphasize rapid-onboarding of key accounts, leverage modular commercialization plans, and pursue multi-channel payer strategies to maximize reimbursement and uptake for LYMPHIR and other products.